News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
23,268 Results
Type
Article (4696)
Company Profile (3)
Press Release (18569)
Section
Business (8588)
Career Advice (115)
Deals (1395)
Drug Delivery (12)
Drug Development (4109)
Employer Resources (20)
FDA (723)
Job Trends (1048)
News (14316)
Policy (1883)
Tag
Academia (110)
Alliances (1996)
Alzheimer's disease (29)
Antibody-drug conjugate (ADC) (17)
Approvals (715)
Bankruptcy (7)
Best Places to Work (662)
Breast cancer (8)
Cancer (38)
Cardiovascular disease (7)
Career advice (90)
CAR-T (5)
Cell therapy (10)
Clinical research (2715)
Collaboration (14)
COVID-19 (920)
C-suite (9)
Data (26)
Diagnostics (176)
Diversity, equity & inclusion (7)
Drug pricing (14)
Duchenne muscular dystrophy (9)
Earnings (1902)
Employer branding (6)
Employer resources (19)
Events (1866)
Executive appointments (23)
FDA (733)
Funding (12)
Gene editing (7)
Gene therapy (22)
GLP-1 (72)
Government (491)
Healthcare (633)
Infectious disease (935)
Inflammatory bowel disease (10)
Interviews (12)
IPO (353)
IRA (11)
Job creations (413)
Job search strategy (85)
Layoffs (42)
Legal (542)
Lung cancer (8)
Management (6)
Medical device (83)
Medtech (83)
Mergers & acquisitions (1044)
Metabolic disorders (25)
Neuroscience (34)
NextGen Class of 2024 (226)
Non-profit (105)
Northern California (35)
Obesity (13)
Opinion (43)
Patents (10)
People (4014)
Phase I (808)
Phase II (1087)
Phase III (1290)
Pipeline (18)
Podcasts (17)
Policy (16)
Postmarket research (201)
Preclinical (236)
Radiopharmaceuticals (6)
Rare diseases (19)
Real estate (244)
Recruiting (7)
Regulatory (980)
Research institute (129)
Resumes & cover letters (21)
RSV (15)
Sickle cell disease (9)
Southern California (19)
Startups (287)
The Weekly (17)
United States (271)
Vaccines (326)
Weight loss (21)
Date
Last 7 days (27)
Last 30 days (90)
Last 365 days (1107)
2024 (1005)
2023 (1160)
2022 (2821)
2021 (2692)
2020 (2119)
2019 (1257)
2018 (1059)
2017 (1257)
2016 (1142)
2015 (1414)
2014 (862)
2013 (730)
2012 (921)
2011 (1019)
2010 (752)
Location
Africa (85)
Asia (1458)
Australia (197)
California (60)
Canada (19)
China (6)
Connecticut (13)
Europe (3976)
Florida (8)
Japan (7)
Maryland (16)
Massachusetts (53)
New Jersey (13)
New York (56)
North Carolina (8)
Northern California (35)
Pennsylvania (16)
South America (80)
Southern California (19)
Washington State (7)
23,268 Results for "pfizer".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug development
5 Sickle Cell Therapies to Watch Following Pfizer’s Oxbryta Exit
In the wake of Pfizer’s voluntary market withdrawal of the popular sickle cell disease therapy,
BioSpace
looks at five investigational drugs currently making their way through the pipeline.
October 21, 2024
·
4 min read
·
Kate Goodwin
Podcast
Pfizer’s Q3 Earnings Win, Deals Galore, Countdown to Election, More
Pfizer, Sanofi and others report Q3 beats; AbbVie, Roche and Novartis strike big deals; the 2024 presidential election looms; and
BioSpace
takes a look back at 10 years of NextGen, our annual pick of young biotechs to watch.
October 30, 2024
·
1 min read
·
Heather McKenzie
Sickle Cell Disease
Pfizer’s Oxbryta Withdrawal Leaves Sickle Cell Community Scrambling, Investors Reeling
Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in sales by the end of the decade, has left patients and healthcare providers with few options, while investors question the pharma giant’s dealmaking prowess.
September 27, 2024
·
7 min read
·
Annalee Armstrong
RSV
Pfizer Wins FDA Approval of RSV Vaccine for Broader Adult Population
Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age. Tuesday’s label expansion covers younger adults who are deemed at higher risk of RSV-related lower respiratory tract disease.
October 23, 2024
·
2 min read
·
Tristan Manalac
Vaccines
CDC Panel Recommends Merck and Pfizer Pneumococcal Vaccines for Adults Aged 50–64
The CDC’s Advisory Committee on Immunization Practices on Wednesday backed the use of Merck’s Capvaxive and Pfizer’s Prevnar 20 in adults between 50-64 years of age, opening a bigger market for the respective companies.
October 24, 2024
·
2 min read
·
Tristan Manalac
Approvals
Pfizer Wins FDA Nod for Hemophilia Therapy Amid Activist Investor Challenge
The approval makes Pfizer’s Hympavzi the first once-weekly subcutaneous prophylactic injection for hemophilia B in the U.S., according to the company, which is currently embroiled in a row with activist investor Starboard Value.
October 14, 2024
·
2 min read
·
Tristan Manalac
Editorial
Analysts Rally Around Pfizer CEO Amid Starboard Challenge
Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the company’s leadership. However, analysts are supportive of the embattled executive.
October 25, 2024
·
4 min read
·
Greg Slabodkin
RSV
Merck, Pfizer Tout Promising Respective Data in RSV With High Rates of Prevention
Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory syncytial virus-associated infections in infants, while Pfizer’s RSV vaccine Abrysvo showed 90% effectiveness at preventing the most severe RSV cases in adults 60 years and older.
October 18, 2024
·
2 min read
·
Tristan Manalac
Podcast
BMS’ Schizophrenia Approval, Pfizer’s Sudden Sickle Cell Withdrawal and Roche’s Pharma Day
Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; new IVF and abortion laws could derail women’s health research; Roche touts CDK inhibitor deal and obesity pipeline and
BioSpace
heads to Meeting on the Mesa.
October 2, 2024
·
1 min read
·
Heather McKenzie
Earnings
Pfizer Exceeds Wall Street’s Q3 Expectations Amid Activist Investor Pressure
CEO Albert Bourla, who is under attack from activist investor Starboard Value, got a much-needed victory on Tuesday as Pfizer reported that third-quarter revenue and adjusted profit beat the analysts’ consensus.
October 29, 2024
·
2 min read
·
Greg Slabodkin
1 of 2,327
Next
